Medindia

X

Key Cellular Pathway in Prostate Cancer Identified

by Sheela Philomena on  February 11, 2014 at 10:46 AM Cancer News   - G J E 4
SPOP protein is found to be the key regulator of androgen receptor activity that prevents uncontrolled growth of cells in the prostate and thus helps prevent prostate cancer, reveals research. The findings appear in the journal Cell Reports.
 Key Cellular Pathway in Prostate Cancer Identified
Key Cellular Pathway in Prostate Cancer Identified
Advertisement

"By uncovering this new and important pathway of androgen receptor destruction, we may one day be able to develop more effective treatments for a substantial proportion of prostate cancer patients who have developed resistance to standard antiandrogen therapy," says Haojie Huang, Ph.D., Mayo Clinic biochemist and senior author of the paper.

Advertisement
SPOP mutations have been detected in approximately 15 percent of prostate cancer cases. In addition, it has been shown that in about 35 percent of prostate cancers, the SPOP protein is expressed at abnormally low levels. Despite its prevalence in prostate cancer, it was not known whether or how SPOP defects contributed to tumor development. What the research team discovered is that SPOP is an enzyme that selectively destroys androgen receptor protein. Failure to do so due to alterations in SPOP results in overabundance of androgen receptor, a master regulator of prostate cancer cell growth.

The Mayo Clinic research team made four major discoveries:
  • The antiandrogen receptor is a bona fide degradation substrate of SPOP.
  • Androgen receptor splicing variants are resistant to SPOP-mediated degradation.
  • Prostate cancer-associated SPOP mutants cannot bind to and promote androgen receptor degradation.
  • Androgens antagonize, but antiandrogens promote SPOP-mediated degradation of androgen receptor.


Prostate Cancer Background

Prostate cancer is the second most common cause of cancer in men and the second leading cause of cancer death in American men, with over 913,000 new cases and over 261,000 deaths worldwide each year. Because of the widespread disability and death that prostate cancer causes, finding new strategies to develop better treatments is an important public health goal.

Androgen receptor is essential for normal prostate cell growth and survival. It is also important for initiation and progression of prostate cancer. Androgen deprivation therapy, including chemical castration and/or antiandrogen therapy, is the mainstay for treating advanced/disseminated prostate cancer. However, tumors almost always reoccur two to three years after initial response and relapse into a disease called castration-resistant prostate cancer. Development of this therapy-resistant symptom is related to a persistent activation of androgen receptor.

Source: Eurekalert
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All